ASND - Ascendis Pharma A/S

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Ascendis Pharma A/S

Tuborg Boulevard 5
Hellerup 2900
45 70 22 22 44

Full Time Employees137

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael Wolff JensenChairman, Sr. VP & Gen. CounselN/AN/A1971
Mr. Jan Møller MikkelsenPres, CEO, Member of Exec. Board & Exec. DirectorN/AN/A1960
Mr. Scott T. SmithCFO, Sr. VP & Member of Exec. BoardN/AN/A1974
Mr. Peter RasmussenVP of Fin. & Principal Accounting OfficerN/AN/A1969
Ms. Lotte SønderbjergChief Admin. Officer & Sr. VPN/AN/A1961
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Corporate Governance

Ascendis Pharma A/S’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.